Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 · New England Journal of Medicine · 4,204 citations
https://doi.org/10.1056/nejmoa1809615
S
Sherene Loi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.2K
Papers
78.4K
Citations
126
h-index
394
i10-index
Sherene Loi is an academic researcher from The University of Melbourne. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 126, co-authored 1028 publications.
ORCID: 0000-0001-6137-9171Papers by this author
worksFulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 · The Lancet Oncology · 1,795 citations
https://doi.org/10.1016/s1470-2045(15)00613-0
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · The Lancet · 1,743 citations
https://doi.org/10.1016/s0140-6736(20)32531-9
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
2013 · Journal of Clinical Oncology · 1,618 citations
https://doi.org/10.1200/jco.2011.41.0902
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015 · New England Journal of Medicine · 1,569 citations
https://doi.org/10.1056/nejmoa1505270
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
2019 · New England Journal of Medicine · 1,275 citations
https://doi.org/10.1056/nejmoa1914609
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat